Therapeutic blood clots activated by mRNA could cushion the blow of osteoarthritis

University of Wisconsin–Madison researchers have developed a promising technique for treating osteoarthritis using therapeutic blood clots activated by messenger RNA.

Osteoarthritis is the most common form of arthritis, affecting roughly 33 million adults in the United States, according to the Centers for Disease Control and Prevention. It occurs when cartilage in key joints like the knees and hips deteriorates, causing pain and stiffness and impeding mobility.

In a paper published in the journal Bioactive Materials, the UW–Madison research team led by William Murphy, a professor of biomedical engineering and orthopedics and rehabilitation, details its new approach. With further development, it could one day offer a more effective option than treatments such as steroid injections, hyaluronic acid injections or even joint replacement surgeries.

“The best-case scenario is that this could be an injectable or implantable treatment for patients who have advanced osteoarthritis,” says Murphy. “This would be an alternative to the existing methods for treatment, which generally don’t show a high level of long-term success.”

Following the lead of his lab’s previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon mineral-coated microparticles to deliver mRNA that encodes for production of a protein that supports cartilage formation.

First, the team takes bone marrow aspirate (liquid bone marrow) and peripheral blood samples from a patient, mixes in the microparticles, and then forms the mixture into a blood clot. Then the mRNA-activated clot gets delivered to the site of the damage.

“This all happens in the same surgery,” says Murphy, whose lab specializes in therapies that leverage biologically inspired materials. “This is all intra-operative, and it uses materials derived from the patient.”

Whereas existing treatments such as arthroscopic chondroplasties can lead to the formation of fresh fibrocartilage tissue, that material doesn’t boast the same mechanical properties of joint cartilage. It also degrades more quickly. Unlike traditional tissue engineering approaches, however, the new method doesn’t require the use of a synthetic scaffold material upon which to grow cells.

After seeing success in rabbit models, the group will test its treatment strategy in a larger animal model before proceeding toward human clinical trials.

Murphy says his group is exploring the same approach to treating large skeletal muscle and bone defects as well.

University of Wisconsin–Madison researchers have developed a promising technique for treating osteoarthritis using therapeutic blood clots activated by messenger RNA.

Osteoarthritis is the most common form of arthritis, affecting roughly 33 million adults in the United States, according to the Centers for Disease Control and Prevention. It occurs when cartilage in key joints like the knees and hips deteriorates, causing pain and stiffness and impeding mobility.

In a paper published in the journal Bioactive Materials, the UW–Madison research team led by William Murphy, a professor of biomedical engineering and orthopedics and rehabilitation, details its new approach. With further development, it could one day offer a more effective option than treatments such as steroid injections, hyaluronic acid injections or even joint replacement surgeries.

“The best-case scenario is that this could be an injectable or implantable treatment for patients who have advanced osteoarthritis,” says Murphy. “This would be an alternative to the existing methods for treatment, which generally don’t show a high level of long-term success.”

Following the lead of his lab’s previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon mineral-coated microparticles to deliver mRNA that encodes for production of a protein that supports cartilage formation.

First, the team takes bone marrow aspirate (liquid bone marrow) and peripheral blood samples from a patient, mixes in the microparticles, and then forms the mixture into a blood clot. Then the mRNA-activated clot gets delivered to the site of the damage.

“This all happens in the same surgery,” says Murphy, whose lab specializes in therapies that leverage biologically inspired materials. “This is all intra-operative, and it uses materials derived from the patient.”

Whereas existing treatments such as arthroscopic chondroplasties can lead to the formation of fresh fibrocartilage tissue, that material doesn’t boast the same mechanical properties of joint cartilage. It also degrades more quickly. Unlike traditional tissue engineering approaches, however, the new method doesn’t require the use of a synthetic scaffold material upon which to grow cells.

After seeing success in rabbit models, the group will test its treatment strategy in a larger animal model before proceeding toward human clinical trials.

Murphy says his group is exploring the same approach to treating large skeletal muscle and bone defects as well.